Soluble CD163 as a marker of macrophage activity in newly diagnosed patients with multiple sclerosis

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Stilund, Morten ^a,b   Reuschlein, Ann Kathrin ^a   Christensen, Tove ^b   Møller, Holger Jon ^a   Rasmussen, Peter Vestergaard ^a   Petersen, Thor ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CD163 ANTIGEN; IMMUNOGLOBULIN G; CELL SURFACE RECEPTOR; DIFFERENTIATION ANTIGEN; LEUKOCYTE ANTIGEN;

ADOLESCENT; ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CELL FUNCTION; CEREBROSPINAL FLUID ANALYSIS; COHORT ANALYSIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOMODULATION; INNATE IMMUNITY; MACROPHAGE; MACROPHAGE ACTIVATION; MAJOR CLINICAL STUDY; MALE; MOLECULAR WEIGHT; MULTIPLE SCLEROSIS; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; RECEIVER OPERATING CHARACTERISTIC; METABOLISM;

ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MACROPHAGES; MULTIPLE SCLEROSIS; RECEPTORS, CELL SURFACE;

EID: 84902313483     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0098588     Document Type: Article

References (44)

1. Compston A, Coles A (2002) Multiple sclerosis. Lancet 359: 1221-1231. (Pubitemid 34304266)
2. Compston A, Coles A (2008) Multiple sclerosis. Lancet 372: 1502-1517.
3. Kipp M, van der Valk P, Amor S (2012) Pathology of multiple sclerosis. CNS Neurol Disord Drug Targets 11: 506-517.
4. Lucchinetti C, Brück W, Parisi J, Scheithauer B, Rodriguez M, et al. (2000) Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 47: 707-717. (Pubitemid 30390191)
5. Kornek B, Lassmann H (2003) Neuropathology of multiple sclerosis-new concepts. Brain Res Bull 61: 321-326.
6. Lassmann H, van Horssen J (2011) The molecular basis of neurodegeneration in multiple sclerosis. FEBS Lett 585: 3715-3723.
7. Mayo L, Quintana FJ, Weiner HL (2012) The innate immune system in demyelinating disease. Immunol Rev 248: 170-187.
8. Zhang Z, Zhang Z-Y, Schittenhelm J, Wu Y, Meyermann R, et al. (2011) Parenchymal accumulation of CD163+ macrophages/microglia in multiple sclerosis brains. J Neuroimmunol 237: 73-79.
9. Vogel DYS, Vereyken EJF, Glim JE, Heijnen PDAM, Moeton M, et al. (2013) Macrophages in inflammatory multiple sclerosis lesions have an intermediate activation status. J Neuroinflammation 10: 35.
10. Fabriek BO, Van Haastert ES, Galea I, Polfliet MMJ, Döpp ED, et al. (2005) CD163-positive perivascular macrophages in the human CNS express molecules for antigen recognition and presentation. Glia 51: 297-305. (Pubitemid 41532105)
11. Verreck FAW, de Boer T, Langenberg DML, van der Zanden L, Ottenhoff THM (2006) Phenotypic and functional profiling of human proinflammatory type-1 and anti-inflammatory type-2 macrophages in response to microbial antigens and IFN-gamma- and CD40L-mediated costimulation. J Leukoc Biol 79: 285-293. (Pubitemid 44831160)
12. Ambarus CA, Krausz S, van Eijk M, Hamann J, Radstake TRDJ, et al. (2012) Systematic validation of specific phenotypic markers for in vitro polarized human macrophages. J Immunol Methods 375: 196-206.
13. Durafourt BA, Moore CS, Zammit DA, Johnson TA, Zaguia F, et al. (2012) Comparison of polarization properties of human adult microglia and blood-derived macrophages. Glia 60: 717-727.
14. Galea J, Cruickshank G, Teeling JL, Boche D, Garland P, et al. (2012) The intrathecal CD163-haptoglobin-hemoglobin scavenging system in subarachnoid hemorrhage. J Neurochem 121: 785-792.
15. Davis BH, Zarev PV (2005) Human monocyte CD163 expression inversely correlates with soluble CD163 plasma levels. Cytometry B Clin Cytom 63: 16-22. (Pubitemid 40096840)
16. Fabriek BO, Moller HJ, Vloet RP, van Winsen LM, Hanemaaijer R, et al. (2007) Proteolytic shedding of the macrophage scavenger receptor CD163 in multiple sclerosis. J Neuroimmunol 187: 179-186. (Pubitemid 47001547)
17. Moller HJ, Hald K, Moestrup SK (2002) Characterization of an enzyme-linked immunosorbent assay for soluble CD163. Scand J Clin Lab Invest 62: 293-299.
18. Moller HJ (2012) Soluble CD163. Scand J Clin Lab Invest 72: 1-13.
19. Teunissen C, Menge T, Altintas A, Alvarez-Cermeno JC, Bertolotto A, et al. (2013) Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis. Mult Scler.
20. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, et al. (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69: 292-302.
21. Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33: 1444-1452.
22. Teunissen CE, Petzold A, Bennett JL, Berven FS, Brundin L, et al. (2009) A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology 73: 1914-1922.
23. R N (2003) Stata tip 1: The eform() option of regress. In: Newton HJ, editor. Stata Technical Journal. Stata Technical Journal: StataCorp LP.
24. Nockher WA, Wick M, Pfister HW (1999) Cerebrospinal fluid levels of soluble CD14 in inflammatory and non-inflammatory diseases of the CNS: upregulation during bacterial infections and viral meningitis. J Neuroimmunol 101: 161-169. (Pubitemid 29516457)
25. Fabriek BO, van Bruggen R, Deng DM, Ligtenberg AJM, Nazmi K, et al. (2009) The macrophage scavenger receptor CD163 functions as an innate immune sensor for bacteria. Blood 113: 887-892.
26. Högger P, Sorg C (2001) Soluble CD163 inhibits phorbol ester-induced lymphocyte proliferation. Biochem Biophys Res Commun 288: 841-843. (Pubitemid 33140958)
27. Brück W, Porada P, Poser S, Rieckmann P, Hanefeld F, et al. (1995) Monocyte/macrophage differentiation in early multiple sclerosis lesions. Ann Neurol 38: 788-796.
28. Moller HJ, Aerts H, Gronbaek H, Peterslund NA, Hyltoft Petersen P, et al. (2002) Soluble CD163: a marker molecule for monocyte/macrophage activity in disease. Scand J Clin Lab Invest Suppl 237: 29-33.
29. Moller HJ, de Fost M, Aerts H, Hollak C, Moestrup SK (2004) Plasma level of the macrophage-derived soluble CD163 is increased and positively correlates with severity in Gaucher's disease. Eur J Haematol 72: 135-139. (Pubitemid 38161162)
30. Baeten D, Moller HJ, Delanghe J, Veys EM, Moestrup SK, et al. (2004) Association of CD163+ macrophages and local production of soluble CD163 with decreased lymphocyte activation in spondylarthropathy synovitis. Arthritis Rheum 50: 1611-1623. (Pubitemid 38608084)
31. Hiraoka A, Horiike N, Akbar SM, Michitaka K, Matsuyama T, et al. (2005) Soluble CD163 in patients with liver diseases: very high levels of soluble CD163 in patients with fulminant hepatic failure. J Gastroenterol 40: 52-56. (Pubitemid 40796332)
32. Trapp BD, Nave K-A (2008) Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci 31: 247-269.
33. Frischer JM, Bramow S, Dal-Bianco A, Lucchinetti CF, Rauschka H, et al. (2009) The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 132: 1175-1189.
34. Romme Christensen J, Börnsen L, Khademi M, Olsson T, Jensen PE, et al. (2013) CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis. Mult Scler 19: 877-884.
35. Androdias G, Reynolds R, Chanal M, Ritleng C, Confavreux C, et al. (2010) Meningeal T cells associate with diffuse axonal loss in multiple sclerosis spinal cords. Ann Neurol 68: 465-476.
36. Timmermann M, Buck F, Sorg C, Högger P (2004) Interaction of soluble CD163 with activated T lymphocytes involves its association with non-muscle myosin heavy chain type A. Immunol Cell Biol 82: 479-487. (Pubitemid 39421057)
37. Adams CW (1988) Perivascular iron deposition and other vascular damage in multiple sclerosis. J Neurol Neurosurg Psychiatry 51: 260-265.
38. Mehta V, Pei W, Yang G, Li S, Swamy E, et al. (2013) Iron is a sensitive biomarker for inflammation in multiple sclerosis lesions. PLoS One 8: e57573.
39. Hametner S, Wimmer I, Haider L, Pfeifenbring S, Brück W, et al. (2013) Iron and neurodegeneration in the multiple sclerosis brain. Ann Neurol.
40. Ellwardt E, Zipp F (2014) Molecular mechanisms linking neuroinflammation and neurodegeneration in MS. Exp Neurol.
41. Mosser DM, Edwards JP (2008) Exploring the full spectrum of macrophage activation. Nat Rev Immunol 8: 958-969.
42. Skarica M, Eckstein C, Whartenby KA, Calabresi PA (2011) Novel mechanisms of immune modulation of natalizumab in multiple sclerosis patients. J Neuroimmunol 235: 70-76.
43. Carpintero R, Brandt KJ, Gruaz L, Molnarfi N, Lalive PH, et al. (2010) Glatiramer acetate triggers PI3K d/Akt and MEK/ERK pathways to induce IL-1 receptor antagonist in human monocytes. Proc Natl Acad Sci U S A 107: 17692-17697.
44. Xia J, Broadhurst DI, Wilson M, Wishart DS (2013) Translational biomarker discovery in clinical metabolomics: an introductory tutorial. Metabolomics 9: 280-299.